Takeda's exkivity® (mobocertinib) receives approval from the nmpa of china, becoming the first and only therapy available for patients with egfr exon20 insertion+ nsclc

Osaka, japan & cambridge, mass.--( business wire )--takeda (tse:4502/nyse:tak) today announced that exkivity® (mobocertinib) has been approved by the national medical products administration (nmpa) of china for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. exkivity has shown clinically meaningful and durable responses in patients with locally advanced or metastatic egfr exon20 insertion+ nsclc and is now the first and only treatment available for this patient population in china. exkivity, an oral tyrosine kinase inhibitor designed to target exon20 insertions, was reviewed as part of the nmpa's breakthrough therapy program. full approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial.
TAK Ratings Summary
TAK Quant Ranking